Spanish nutraceuticals company Puleva Biotech, a unit of food major Ebro Puleva, has reported a 7% decline to €716,000 (US$873,000) in first half operating profits, hurt by large expenses to promote its new GH-28 probiotics line.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Net profits also fell 23% to €628,000 on revenues up 12% to €3.76m, the company said in a statement.
While turnover was boosted by brisk sales of its CV-17 “Omega3” fatty acid it was not enough to offset high costs to market GH-28 in the international markets before its slated launch later this year.
Puleva Biotech said its third-party research business performed well in the period. The unit is developing functional compounds for Ebro’s milk brand Lactimilk and for Ebro’s rice franchise.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
